CD34 and neoplasm: After determining the number of blood vessels in tumor samples from 29 patients by immunohistochemistry, using an antibody against CD34+, which is a marker of the blood vessel endothelium (Figure 5C), we classified the tumor samples in two groups: high or low levels of miR-141.